To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Dr. Pravin Dugel – Highlights from Day 1 of Retina Subspecialty Day 2017Findings from neovascular AMD studies a highlight from Day 1
/ Uncategorized /by retinalconsultantsFindings from neovascular AMD studies a highlight from Day 1 NEW ORLEANS – The 48-week results of the HAWK and HARRIER studies on brolucizumab (Novartis) for the treatment of neovascular age-related macular degeneration (AMD) were one of the highlights from Day 1 at Retina Subspecialty Day. Pravin Dugel, MD, (Phoenix, Ariz.) first described the antibody […]
Novartis’ eye drug clearly works, but edging out Eylea won’t be easy – Dr. Pravin U. Dugel
/ Uncategorized /by retinalconsultantsDive Brief: Novartis AG’s investigational eye drug bested Regeneron Pharmaceutical Inc.’s Eylea on additional secondary endpoints of two late-stage studies, bolstering the treatment’s potential to go head to head with Regeneron’s market leader. In HAWK trial, 35% fewer patients had intra-retinal fluid (IRF) and/or sub-retinal fluid (SRF) after 16 weeks of taking Novartis’ brolucizumab 6 mg versus […]
Novartis’ VEGF inhibitor demonstrates clinically relevant anatomic, visual gains – Dr. Pravin Dugel
/ Uncategorized /by retinalconsultantsMEETING NEWS American Academy of Ophthalmology Meeting NEW ORLEANS — Novartis’ first-in-kind molecule brolucizumab achieved clinically relevant anatomic and visual acuity gains in patients with age-related macular degeneration with every-12-week dosing, according to a speaker. Two dosages of the single-chain antibody fragment VEGF inhibitor were compared with Eylea (aflibercept, Regeneron) in two phase 3 trials, […]
Dr. Derek Kunimoto First in Arizona to Use B&L’s New Bi-Blade Cutter, Vitrectomy Procedure
/ Uncategorized /by retinalconsultantsRetinal Consultants of Arizona and the Retina Research Institute is dedicated to providing the most advanced, personalized patient care in Arizona. Our practice is at the forefront of implementing the latest technologies available for the diagnosis, management and treatment of retina and vitreous disease and conditions – all designed for the highest quality patient care […]
RCA’s Dr. Derek Y. Kunimoto Graduates From AAO Leadership Development Program
/ Media /by retinalconsultantsPhoenix – December 8th, 2017 – On Monday, November 13th during the Society Presidents’ Recognition and Awards Session held in conjunction with AAO 2017 in New Orleans, Dr. Derek Y. Kunimoto was recognized for completing his participation in the Academy’s Leadership Development Program XIXI, Class of 2017. Dr. Kunimoto was among a select group of […]
Dr. Pravin Dugel: “Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness”
/ Uncategorized /by retinalconsultantsNovartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept Significantly […]
Spectra Eye Institute Opens Second Location at Retinal Consultants of Arizona – North Phoenix
/ Media /by retinalconsultantsPhoenix – October 15th, 2017 – Spectra Eye Institute – a leading, private outpatient surgical center dedicated to comprehensive ophthalmic surgical care – has opened its North Phoenix location inside the new Retinal Consultants of Arizona North Phoenix facility at Greenway and the I-17. The new 9,200 square foot surgical facility is set up for […]
Retinal Research Institute First to Enroll, and the First Site in the World to Administer New Injection to Patients with AMD!
/ Uncategorized /by retinalconsultantsGraybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular Degeneration – Novel Injectable Formulation for Potential Twice Per Year Treatment – Redwood City, CA – September 19, 2017 – Graybug Vision, Inc., a clinical-stage, venture-held pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration […]
Promising Drugs in Pipeline Debut at Euretina 2017
/ Uncategorized /by retinalconsultantsPravin U. Dugel, MD, Managing Partner, Retinal Consultants of Arizona; Clinical Professor, USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California; Physician Executive Director, Phoenix Eye Institute, Banner University Medical Center, Phoenix, Arizona describes the promising new drugs coming up the pipeline at the 17th Euretina Congress in Barcelona, Spain. These include next generation drugs […]
RCA Diabetes Support Group Program
/ Uncategorized /by retinalconsultantsRetinal Consultants of Arizona will offer a Diabetic Eye Disease Support Group program on November 18th. Our staff will be on hand to meet with you and answer all your questions about Diabetic Eye Disease. In the spirit of support groups, you will be able to meet others to learn from their experiences, or to […]